Recent studies indicated that interleukin-6 (IL-6) is involved in the pathogenesis of NMO [32], [33], and blockade of the IL-6 pathway, by tocilizumab, a humanized monoclonal anti-IL-6 receptor antibody, has been suggested as a new therapy for NMOSD [34]. This evidence concerns the gene IL6 and neuromyelitis optica.